Interferon Gamma-1B

證據等級: L5

預測適應症: 10 個

Interferon Gamma-1b: From Chronic Granulomatous Disease to Heart Disease

One-Sentence Summary

Interferon gamma-1b is an immunomodulatory cytokine originally indicated for chronic granulomatous disease (CGD) and severe malignant osteopetrosis. The TxGNN model predicts it may be effective for Heart Disease, but this direction is currently supported by 0 directly relevant clinical trials and 0 directly relevant publications out of 50 trials and 5 papers retrieved — the evidence collected is dominated by keyword-matching noise rather than true drug-disease evidence.

Quick Overview

Item	Content
Original Indication	Chronic Granulomatous Disease (CGD); severe, malignant osteopetrosis (per repurposing rationale; not present in structured license data)
Predicted New Indication	Heart Disease
TxGNN Prediction Score	99.99%
Evidence Level	L4
US Market Status	未上市 (Not marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Formal mechanism-of-action (MOA) data for this candidate is flagged as a data gap in the evidence pack. Based on the information available, interferon gamma-1b is known to activate macrophages, enhance phagocytic killing, and promote a pro-inflammatory immune response — the basis for its approved use in chronic granulomatous disease and malignant osteopetrosis. This is a fundamentally pro-inflammatory mechanism.

Heart disease, as a broad category, generally responds better to anti-inflammatory or cardioprotective mechanisms rather than immune activation. None of the 50 clinical trials retrieved for this pairing actually test interferon gamma-1b in a cardiac indication — the search results are populated by unrelated exercise-rehabilitation trials, trials of other drugs (liraglutide, ritlecitinib, cyclosporine, ALKS 4230, etc.), and general inflammation-biomarker studies. This is consistent with the pipeline’s own assessment that this match is likely a keyword/pipeline mismatch rather than genuine mechanistic evidence.

The single literature item with plausible relevance is a case report of aspergillus constrictive pericarditis in a CGD patient — this describes a disease complication in a patient population that happens to use this drug, not a treatment effect on heart disease. Overall, the mechanistic rationale for this specific pairing is weak, and the directionality (pro-inflammatory vs. the anti-inflammatory/cardioprotective mechanisms typically sought in heart disease) raises concern rather than support.

Clinical Trial Evidence

None of the retrieved trials directly test interferon gamma-1b for heart disease. The table below lists the top trials returned by the search, with their assessed relevance noted — all were graded “C” (not relevant / keyword mismatch):

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03652519	NA	Completed	72	Aerobic exercise rehabilitation in multiple sclerosis; does not involve interferon gamma-1b
NCT04356248	NA	Completed	106	High-intensity training vs. standard training in MS; unrelated to the drug
NCT03672812	Phase 3	Completed	50	Tests liraglutide in brain-death organ donors, not interferon gamma-1b
NCT07099911	NA	Recruiting	20	Neuromuscular electrical stimulation for glucose control; unrelated
NCT05650333	Phase 1	Completed	15	PK/PD of ritlecitinib (JAK inhibitor) in alopecia areata; not this drug
NCT05027958	Early Phase 1	Completed	17	Bronchoscopic mycobacterial antigen instillation study; not a drug intervention trial for heart disease
NCT02489383	NA	Unknown	60	Continuous vs. interval aerobic exercise in asthma; unrelated
NCT00974142	Phase 1/2	Completed	43	Oral cyclosporine in advanced COPD; not this drug
NCT03904277	N/A	Completed	28	Observational study of patent foramen ovale size; no drug intervention
NCT02799095	Phase 1/2	Completed	243	ALKS 4230 ± pembrolizumab in solid tumors; not this drug

Note: 40 additional trials were retrieved but not yet graded for relevance (“pending”); a manual scan of titles found none that test interferon gamma-1b specifically for a cardiac indication.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28990950	2017	Case Report	Turk Kardiyoloji Dernegi Arsivi	Pediatric CGD patient with constrictive aspergillus pericarditis and congestive heart failure — a disease complication in a CGD patient, not a treatment study of the drug for heart disease
37180421	2022	Review	Therapeutic Advances in Rare Disease	Systematic review of interventions in Friedreich ataxia; unrelated to heart disease indication
31020218	2018	Case Report	European Heart Journal – Case Reports	Mycobacterium chimaera prosthetic valve endocarditis after cardiac surgery; does not involve this drug
21131468	2011	Validation Study	American Journal of Respiratory and Critical Care Medicine	Validation of the 6-minute-walk test in idiopathic pulmonary fibrosis; unrelated to this drug or heart disease

None of the retrieved literature demonstrates a treatment effect of interferon gamma-1b on heart disease.

US Market Information

Interferon gamma-1b is currently not marketed in this jurisdiction, and no license/NDA records were found (0 licenses on file).

Safety Considerations

Please refer to the package insert for safety information. Structured warning, contraindication, and drug-interaction data were not available at this data cutoff (2026-08-13); TFDA labeling has not yet been retrieved (see Conclusion, below).

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted pairing (interferon gamma-1b → heart disease) is supported only by a raw TxGNN model score, with no clinical trial or literature evidence that directly tests the drug in a cardiac indication — the retrieved evidence is best explained as pipeline/keyword noise. The drug’s known pro-inflammatory mechanism (macrophage activation) also runs counter to the anti-inflammatory/cardioprotective mechanisms typically sought in heart disease, making the biological rationale weak.

To proceed, the following is needed:

Official TFDA label/package insert (warnings, contraindications) — currently a blocking data gap
Verified DrugBank mechanism-of-action data
A disease-specific literature/trial search (e.g., restricting “heart disease” to a defined subtype) rather than the broad category used here, to rule out further keyword mismatch
If genuine mechanistic or preclinical rationale for a specific cardiac subtype emerges, re-evaluate at L3/L4 with targeted evidence collection

Additional note on lower-ranked candidates: Ranks 2–10 (Jeune syndrome, orofacial clefting, Pierre Robin syndrome variants, chromosomal deletions, Laubry-Pezzi syndrome, interventricular septum aneurysm) returned zero clinical trials and zero or off-target literature, corresponding to Evidence Level L5 (model prediction only). These are not viable candidates for further evaluation at this time.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.